Current Liabilities
Accrued interest
Royalty Pharma Accrued interest decreased by 77.2% to $25.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 31.6%, from $19.22M to $25.30M. Over 5 years (FY 2020 to FY 2025), Accrued interest shows an upward trend with a 21.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026
How to read this metric
An increase typically tracks with the total debt load and the timing of interest payment cycles.
Detailed definition
Accrued interest represents the interest expense that has accumulated on debt obligations but has not yet reached its sc...
Peer comparison
Comparable across companies with similar capital structures and debt maturity profiles.
Metric ID:
accrued_interestHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.90M | $16.73M | $57.70M | $13.20M | $54.16M | $13.20M | $54.16M | $13.20M | $54.16M | $12.60M | $51.68M | $12.60M | $56.25M | $38.41M | $98.06M | $19.22M | $85.61M | $29.04M | $110.82M | $25.30M |
| QoQ Change | — | -61.0% | +244.8% | -77.1% | +310.3% | -75.6% | +310.3% | -75.6% | +310.3% | -76.7% | +310.3% | -75.6% | +346.6% | -31.7% | +155.3% | -80.4% | +345.4% | -66.1% | +281.6% | -77.2% |
| YoY Change | — | — | — | — | +26.2% | -21.1% | -6.1% | +0.0% | +0.0% | -4.6% | -4.6% | -4.6% | +3.9% | +205.0% | +89.7% | +52.6% | +52.2% | -24.4% | +13.0% | +31.6% |
Range$12.60M – $110.82M
CAGR-10.5%
Avg YoY Growth+25.6%
Median YoY Growth+1.9%
Accrued interest at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's accrued interest?
- Royalty Pharma (RPRX) reported accrued interest of $25.30M in Q1 2026.
- How has Royalty Pharma's accrued interest changed year-over-year?
- Royalty Pharma's accrued interest increased by 31.6% year-over-year, from $19.22M to $25.30M.
- What is the long-term trend for Royalty Pharma's accrued interest?
- Over 5 years (2020 to 2025), Royalty Pharma's accrued interest has grown at a 21.3% compound annual growth rate (CAGR), from $42.15M to $110.82M.
- What does accrued interest mean?
- Interest that has built up on debt but has not been paid yet.